Fundraising FoxDeuterx
Andover, US · Founded 2012 · Delaware LLC
Find your way into Deuterx
Sign up to see every warm intro you have to Deuterx
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Deuterx team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Founders & leadership
Deuterx was founded in 2012 by Sheila DeWitt.
SD
Sheila DeWittChair, President, CEO & FounderSheila DeWitt is an executive with experience leading drug discovery and development initiatives, including managing multiple biotechnology companies and business units, overseeing deuterated drug portfolio sales to public companies, and directing substantial M&A transactions and R&D operations.
Board
AW
Anthony W. CzarnikBoard director
Reported raises · per SEC filings
Form D private placements$2.2M disclosed across 1 round · 2015
▶$2.2MraisedSep 2015 · 26 investors · BiotechnologyRule 506(b)
▶$2.2MraisedSep 2015 · 26 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Sheila DeWittExecutive Officer, Director
- Anthony W. CzarnikDirector
- Amount sold
- $2.2M
- First sale
- Sep 2015
- Incorporated
- Limited Liability Company, Delaware, 2012
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 4
Building EnginesBuilding Engines is a cloud building operations platform for commercial real estate, acquired by JLL in 2021 for about $300 million.
DelixDelix Therapeutics develops third-generation, non-hallucinogenic neuroplastogens for people with neurological conditions, using a discovery platform to identify novel compounds. Its pipeline includes a Phase 2-ready asset and multiple preclinical programs targeting brain health and neuroplasticity.
Nurix TherapeuticsNurix Therapeutics develops protein degrader-based medicines using proprietary DEL-AI discovery technology to address cancer and autoimmune diseases. The company applies targeted protein degradation to overcome limitations of conventional therapeutic approaches.
Redfin CorpReal Estate & Homes for Sale, Rentals, Mortgages & Agents
Companies working in the same space as Deuterx.
Non-dilutive funding · 1 SBIR/STTR award
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2016 | $294.5K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- Who founded Deuterx?
- Deuterx was founded by Sheila DeWitt in 2012.
- How much funding has Deuterx raised?
- Deuterx has disclosed $2.2M raised across 1 round.
- Where is Deuterx headquartered?
- Deuterx is headquartered in Andover, US.